1st Quarter - Report

ALSTON & BIRD LLP for NOVO NORDISK INC.

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues related to H.R. 1628, American Health Care Act, Section 221.

Foreign entity interest: To the extent that Novo Nordisk Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, Novo Nordisk Fonden.

LobbyistCovered position, as disclosed
MARK RAYDER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1628 (115th)

Health Issues HCR

National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; cost of diabetes generally; H.R. 309, National Clinical Care Commission Act.

Foreign entity interest: To the extent that Novo Nordisk Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, Novo Nordisk Fonden.

LobbyistCovered position, as disclosed
JOYCE E GRESKO —
EARL POMEROY —
MARK RAYDER —
COLIN ROSKEY —
REGINA MARIA SHERICK —
ROBERT SIGGINS —
DANIELLE WHITE —
MARILYN K YAGER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 309 (115th)

Medicare/Medicaid MMM

Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 1953 and S. 830 Treat and Reduce Obesity Act; Medicare diabetes screening generally.

Foreign entity interest: To the extent that Novo Nordisk Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, Novo Nordisk Fonden.

LobbyistCovered position, as disclosed
JOYCE E GRESKO —
MARK RAYDER —
COLIN ROSKEY —
REGINA MARIA SHERICK —
ROBERT SIGGINS —
DANIELLE WHITE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 830 (115th), H.R. 1953 (115th)

Budget/Appropriations BUD

Issues related to National Diabetes Prevention Program. FY17 Labor/HHS/Education Appropriations.

Foreign entity interest: To the extent that Novo Nordisk Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, Novo Nordisk Fonden.

LobbyistCovered position, as disclosed
MARK RAYDER —
REGINA MARIA SHERICK —
ROBERT SIGGINS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.